In This Article:
Roche has introduced its Chest Pain Triage algorithm, designed to rapidly identify acute coronary syndrome (ACS).
This algorithm, part of the company’s cloud-based platform navify Algorithm Suite, aims to improve patient triage in emergency departments (EDs).
Developed in partnership with Universitätsklinikum Heidelberg, Germany, the Chest Pain Triage algorithm utilises cardiac troponin testing and other diagnostic technologies.
It offers healthcare professionals timely data to distinguish between non-cardiac and cardiac chest pain.
The algorithm will identify at-risk individuals by detecting the cases of non-cardiac chest pain, via a definitive Rule-In, Rule-Out, or Observe recommendation as per the guidelines of the European Society of Cardiology (ESC).
According to the company, the algorithm automatically chooses the appropriate ESC 0/1, 0/2, or 0/3 accelerated pathway based on blood sample collection timing.
This feature could minimise needless hospital admissions and related expenses.
For individuals with true ACS, the algorithm claims to accelerate the treatment process by facilitating rapid assessments for chest pain onset over three hours before the initial blood sample.
It also includes a medical dossier to support clinicians and simplify documentation, allowing doctors to copy recommendations and results into the patient's records.
Roche Diagnostics CEO Matt Sause said: "The introduction of our Chest Pain Triage algorithm underscores Roche's commitment to improving care for cardiovascular disease, one of the world’s largest health burdens.
"Our Chest Pain Triage algorithm can help doctors quickly decide who needs urgent cardiac care and who could be discharged sooner. With an early rule-out pathway, we can cut down ED visit times by over three hours.”
The algorithm aligns with Roche's focus on early detection and treatment of cardiovascular conditions.
It is currently available in the Middle East, Asia and Europe, and will be available in the US soon via the navify Algorithm Suite.
This suite hosts clinical algorithms from the company and partners, offering laboratories and hospitals a direct workflow integration via lab information systems (LIS) and electronic health records (EHR).
Earlier this year, Roche's Tina-quant Lipoprotein (a) Gen.2 Molarity assay received 510(k) clearance from the US Food and Drug Administration (FDA).
"Roche introduces algorithm for ACS detection in individuals with chest pain" was originally created and published by Medical Device Network, a GlobalData owned brand.